PacingCure
PacingCure is dedicated to developing precision gene therapies for cardiac diseases, focusing on abnormal electrical properties of the heart. Their mission is to translate scientific discoveries into innovative treatments through cutting-edge science, careful asset selection, and smart execution. They aim to revolutionize cardiac care by targeting disease mechanisms directly and delivering therapies precisely into the disease core, with platforms in clinical development to address high unmet medical needs.
Industries
Nr. of Employees
small (1-50)
PacingCure
Products
AAV-mediated gene therapy project for cardiac pacing dysfunction (TRACTION)
A development program to reprogram cardiomyocytes into pacemaker cells via AAV-mediated delivery of transcriptional regulators, intended to restore physiological heart rate in patients with pacing dysfunction.
AAV-mediated gene therapy project for cardiac pacing dysfunction (TRACTION)
A development program to reprogram cardiomyocytes into pacemaker cells via AAV-mediated delivery of transcriptional regulators, intended to restore physiological heart rate in patients with pacing dysfunction.
Services
Translational preclinical R&D
End-to-end translational research bridging laboratory discoveries to clinical-ready therapeutic candidates, including model development, efficacy testing, and asset selection.
Preclinical optimization of gene delivery and expression control
Optimization and validation of viral vector delivery, transcription factor overexpression strategies, and cell-specific expression control to maximize therapeutic effect and minimize off-target activity.
Clinical program planning for cardiac gene therapies
Identification of clinical indications, definition of endpoints and readouts, and strategic planning to enable clinical entry with regulatory and business considerations.
Translational preclinical R&D
End-to-end translational research bridging laboratory discoveries to clinical-ready therapeutic candidates, including model development, efficacy testing, and asset selection.
Preclinical optimization of gene delivery and expression control
Optimization and validation of viral vector delivery, transcription factor overexpression strategies, and cell-specific expression control to maximize therapeutic effect and minimize off-target activity.
Clinical program planning for cardiac gene therapies
Identification of clinical indications, definition of endpoints and readouts, and strategic planning to enable clinical entry with regulatory and business considerations.
Expertise Areas
- Cardiac gene therapy development
- Translational preclinical research
- Viral vector (AAV) delivery optimization
- Preclinical model development for arrhythmias
Key Technologies
- Adeno-associated virus (AAV) gene delivery
- Transcription factor–based gene expression control
- Cell type-specific regulatory elements
- Engineered heart tissues